FDA breakthrough therapy designation granted for Bayer’s Aliqopa
The decision was primarily based on follow-up data from the pivotal Phase II study CHRONOS-1.
Read More
Tag: non-Hodgkin’s lymphoma
Novartis’ MabThera biosimilar wins EU nod
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
